Sign in
Taking people in United StatesPhase 1

Tests anti-CD19 CAR-T cells for relapsed blood cancers returning after treatment

Tests CAR-T cells in adults with acute lymphoblastic leukemia or large B cell lymphoma.

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Registry title
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
10 people, planned
Started
20 Feb 2024
Expected to end
May 2028
Type of study
Interventional
Treatments tested
  • Anti-CD19 CAR-T cells
Record updated
26 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose CD19-positive blood cancer (lymphoma or leukemia) came back or did not respond to earlier treatment. It tests anti-CD19 CAR-T cells.

Age
18 years or older
Sex
All sexes can join.
Disease stage
CD19-positive cancer that came back or did not respond: non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia/Richter's syndrome, or primary CNS lymphoma. CD19 must be confirmed by a lab test. Cancer came back or did not respond to first-line chemoimmunotherapy, or returned within 12 months of it.
Earlier treatment
Must have had first-line chemoimmunotherapy. No stem cell transplant or CAR-T therapy within 6 weeks before the planned infusion. No other investigational drugs.
Biomarker or test result
CD19-positive cancer, confirmed by immunohistochemistry or flow cytometry.

Main reasons for not taking part

  • Active infection needing treatment, including hepatitis B, hepatitis C (with detectable virus) or HIV
  • Pregnant or breastfeeding
  • Autoimmune disease needing immune-suppressing medicine in the last 6 months
  • Another cancer in the last 2 years (some exceptions)
  • Serious heart disease or certain brain and nerve conditions such as epilepsy or dementia

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Subjects aged ≥ 18 years
  • Histologically confirmed relapsed or refractory CD-19+ malignancy, including: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)/Richter's syndrome, primary CNS lymphoma. CD-19+ must be confirmed by immunohistochemistry or flow cytometry analysis
  • Subjects who are relapsed or refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy
  • ECOG Performance Status ≤ 2
  • Life expectancy > 12 weeks
  • Willing to consent to 15 years of follow-up as part of IRB 110692: Long-Term Evaluation of the Biology and Outcomes of Hematopoietic Stem Cell Transplantation
  • Adequate organ function as defined as:; Hematologic:; Absolute neutrophil count (ANC) ≥ 500/mm3; Platelet count ≥ 10,000/mm3; Hemoglobin ≥ 8 g/dL; Hepatic:; Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Renal:; Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR >30 ml/min/1.73m2
  • For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:; Subjects < 50 years of age:; Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and; Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; Subjects ≥ 50 years of age:; Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or; Had radiation-induced menopause with last menses >1 year ago; or; Had chemotherapy-induced menopause with last menses >1 year ago
  • Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1
  • Recovery to baseline or ≤ Grade 2 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered stable by the treating investigator
  • Adequate venous access
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
  • Step 2 Eligibility Confirmation; The following criteria must be confirmed within 7 days prior to lymphodepletion. If all criteria are not met, lymphodepletion should be delayed; Confirmation of successful CAR-T manufacturing; No evidence or suspicion of an infection; Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR >30 ml/min/1.73m2; No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risk from lymphodepleting chemotherapy or exclude them from treatment with study CAR-T therapy
  • Step 3 Eligibility Confirmation; The following criteria must be confirmed prior to CAR-T therapy. If all criteria are not met, CAR-T therapy should be delayed; No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risks from treatment with CAR-T therapy; Confirmation that washout periods outlined in section 6.6 and Appendix 10 have been followed

Who cannot take part

  • Autologous or allogeneic stem cell transplant or CAR-T therapy within 6 weeks of planned CAR-T cell infusion
  • Receiving other investigational agents
  • Confirmation that washout periods listed in Appendix 10 have been followed
  • Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery
  • The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6). Patients with transformed disease are allowed
  • Known brain metastases or cranial epidural disease. Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment
  • Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3)
  • Subjects taking prohibited medications as described in Section 6.6 and Appendix 10. Unless otherwise stated, a washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment
  • Subjects with active infection that requires systemic treatment
  • History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or seropositive HIV. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study
  • Subjects with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease
  • Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of child bearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study
  • Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:; Cardiovascular disorders:; Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias; Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose; QTc prolongation defined as a QTcF > 500 ms; Known congenital long QT; Left ventricular ejection fraction < 55%; Uncontrolled hypertension defined as ≥ 140/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes; Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/ psychological issues, etc.)

Where in United States

  • Huntsman Cancer InstituteSalt Lake City, United StatesContact: Rachel KingsfordTaking people

About the trial

What the trial wants to find out

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells.

Read full original descriptionShow less

This study will utilize a staggered enrollment design with a safety observation period.

The group in the trial

  • Anti-CD19 CAR-T Cell InfusionTreatment being tested

    Treatment: Anti-CD19 CAR-T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Plain-language title
Tests anti-CD19 CAR-T cells for relapsed blood cancers returning after treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 August 2026